MedKoo Cat#: 522710 | Name: BMS-711939

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMS-711939 is a potent and selective peroxisome proliferator-activated receptor (PPAR) α agonist, with an EC50 of 4 nM for human PPARα and >1000-fold selectivity vs human PPARγ (EC50 = 4.5 μM) and PPARδ (EC50 > 100 μM) in PPAR-GAL4 transactivation assays. BMS-711939 also demonstrated excellent in vivo efficacy and safety profiles in preclinical studies and thus was chosen for further preclinical evaluation.

Chemical Structure

BMS-711939
BMS-711939
CAS# 1000998-62-8

Theoretical Analysis

MedKoo Cat#: 522710

Name: BMS-711939

CAS#: 1000998-62-8

Chemical Formula: C22H20ClFN2O6

Exact Mass: 462.0994

Molecular Weight: 462.86

Elemental Analysis: C, 57.09; H, 4.36; Cl, 7.66; F, 4.10; N, 6.05; O, 20.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BMS-711939; BMS 711939; BMS711939.
IUPAC/Chemical Name
N-(5-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)-2-fluorobenzyl)-N-(methoxycarbonyl)glycine
InChi Key
OPHWZEQODBXRCZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H20ClFN2O6/c1-13-19(25-21(32-13)14-3-5-16(23)6-4-14)12-31-17-7-8-18(24)15(9-17)10-26(11-20(27)28)22(29)30-2/h3-9H,10-12H2,1-2H3,(H,27,28)
SMILES Code
O=C(O)CN(CC1=CC(OCC2=C(C)OC(C3=CC=C(Cl)C=C3)=N2)=CC=C1F)C(OC)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 462.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mukherjee R, Locke KT, Miao B, Meyers D, Monshizadegan H, Zhang R, Search D, Grimm D, Flynn M, O'Malley KM, Zhang L, Li J, Shi Y, Kennedy LJ, Blanar M, Cheng PT, Tino J, Srivastava RA. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. J Pharmacol Exp Ther. 2008 Dec;327(3):716-26. doi: 10.1124/jpet.108.143271. Epub 2008 Sep 17. PubMed PMID: 18799592. 2. Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist Yan Shi, Jun Li, Lawrence J. Kennedy, Shiwei Tao, Andrés S. Hernández, Zhi Lai, Sean Chen, Henry Wong, Juliang Zhu, Ashok Trehan, Ngiap-Kie Lim, Huiping Zhang, Bang-Chi Chen, Kenneth T. Locke, Kevin M. O’Malley, Litao Zhang, Rai Ajit Srivastava, Bowman Miao, Daniel S. Meyers, Hossain Monshizadegan, Debra Search, Denise Grimm, Rongan Zhang, Thomas Harrity, Lori K. Kunselman, Michael Cap, Jodi Muckelbauer, Chiehying Chang, Stanley R. Krystek, Yi-Xin Li, Vinayak Hosagrahara, Lisa Zhang, Pathanjali Kadiyala, Carrie Xu, Michael A. Blanar, Robert Zahler, Ranjan Mukherjee, Peter T. W. Cheng, and Joseph A. Tino Publication Date (Web): April 4, 2016 (Letter) DOI: 10.1021/acsmedchemlett.6b00033